Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results; VetScan UA, a urinalysis solution; and VetScan SA, which is designed to perform urine microscopy. Further, it provides VetScan rapid tests for the detection of various diseases, as well as sells products developed through its patented Orbos discrete lyophilization process to companies for other applications. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Measuring & controlling devices, not elsewhere classified
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABAX
CUSIP00256710
Phone510-675-6500
Debt
Debt-to-Equity RatioN/A
Current Ratio6.02
Quick Ratio5.02
Price-To-Earnings
Trailing P/E Ratio64.34
Forward P/E Ratio56.46
P/E Growth5.51
Sales & Book Value
Annual Sales$244.70 million
Price / Sales7.76
Cash Flow$1.7145 per share
Price / Cash48.41
Book Value$12.81 per share
Price / Book6.48
Profitability
EPS (Most Recent Fiscal Year)$1.29
Net Income$27.17 million
Net Margins11.11%
Return on Equity10.65%
Return on Assets9.12%
Miscellaneous
Employees656
Outstanding Shares22,870,000
Market Cap$1.90 billion
Abaxis (NASDAQ:ABAX) Frequently Asked Questions
What is Abaxis' stock symbol?
Abaxis trades on the NASDAQ under the ticker symbol "ABAX."
How often does Abaxis pay dividends? What is the dividend yield for Abaxis?
Abaxis announced a quarterly dividend on Thursday, April 26th. Stockholders of record on Friday, June 1st will be given a dividend of $0.18 per share on Friday, June 15th. This represents a $0.72 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Thursday, May 31st. This is an increase from Abaxis's previous quarterly dividend of $0.16. View Abaxis' Dividend History.
How will Abaxis' stock buyback program work?
Abaxis announced that its Board of Directors has approved a stock repurchase plan on Wednesday, October 25th 2017, which authorizes the company to buyback $21,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its stock is undervalued.
How were Abaxis' earnings last quarter?
Abaxis Inc (NASDAQ:ABAX) posted its quarterly earnings results on Thursday, April, 26th. The medical research company reported $0.42 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.32 by $0.10. The medical research company earned $67.90 million during the quarter, compared to the consensus estimate of $66.02 million. Abaxis had a net margin of 11.11% and a return on equity of 10.65%. Abaxis's revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.33 EPS. View Abaxis' Earnings History.
What price target have analysts set for ABAX?
9 Wall Street analysts have issued 1 year target prices for Abaxis' stock. Their forecasts range from $48.00 to $65.00. On average, they anticipate Abaxis' stock price to reach $58.3333 in the next year. This suggests that the stock has a possible downside of 29.7%. View Analyst Price Targets for Abaxis.
What is the consensus analysts' recommendation for Abaxis?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abaxis in the last year. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Abaxis.
Who are some of Abaxis' key competitors?
Some companies that are related to Abaxis include MEGGITT PLC/ADR (MEGGY), Cubic (CUB), FARO Technologies (FARO), Nanometrics (NANO), MTS Systems (MTSC), Oxford Instruments (OXINF), Geospace Technologies (GEOS), Know Labs (KNWN), Image Sensing Systems (ISNS), Cemtrex (CETX), Mikros Systems (MKRS), Sierra Monitor (SRMC), Midwest Energy Emissions (MEEC), Mechanical Technology (MKTY) and Visualant (VSUL).
Who are Abaxis' key executives?
Abaxis' management team includes the folowing people:
- Mr. Clinton H. Severson, Chairman & CEO (Age 70)
- Mr. Donald P. Wood, Pres & COO (Age 66)
- Mr. Ross Taylor Jr., CFO, VP of Fin. & Sec. (Age 55)
- Dr. Kenneth P. Aron Ph.D., Chief Technology Officer (Age 65)
- Dr. Craig M. Tockman DVM, VP of Animal Health Sales and Marketing - North America (Age 58)
Has Abaxis been receiving favorable news coverage?
News headlines about ABAX stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Abaxis earned a news and rumor sentiment score of 0.14 on Accern's scale. They also assigned news stories about the medical research company an impact score of 49.50 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Abaxis.
Who are Abaxis' major shareholders?
Abaxis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.52%), Dimensional Fund Advisors LP (3.08%), Wells Fargo & Company MN (2.21%), Nuance Investments LLC (1.79%), Bank of New York Mellon Corp (1.41%) and Renaissance Technologies LLC (1.25%). Company insiders that own Abaxis stock include Achim Henkel, Clinton Severson, Craig Tockman, Donald Peter Wood, Kenneth Aron, Michael D Casey, Prithipal Singh and Richard Bastiani. View Institutional Ownership Trends for Abaxis.
Which major investors are selling Abaxis stock?
ABAX stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Russell Investments Group Ltd., AMI Asset Management Corp, US Bancorp DE, Millennium Management LLC, Bank of New York Mellon Corp, Bard Associates Inc. and Pinebridge Investments L.P.. Company insiders that have sold Abaxis company stock in the last year include Achim Henkel, Craig Tockman, Donald Peter Wood, Kenneth Aron, Michael D Casey and Prithipal Singh. View Insider Buying and Selling for Abaxis.
Which major investors are buying Abaxis stock?
ABAX stock was bought by a variety of institutional investors in the last quarter, including Nuance Investments LLC, Gabelli Funds LLC, BlackRock Inc., Renaissance Technologies LLC, Gamco Investors INC. ET AL, Capital Fund Management S.A., IndexIQ Advisors LLC and Water Island Capital LLC. View Insider Buying and Selling for Abaxis.
How do I buy shares of Abaxis?
Shares of ABAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abaxis' stock price today?
One share of ABAX stock can currently be purchased for approximately $83.00.
How big of a company is Abaxis?
Abaxis has a market capitalization of $1.90 billion and generates $244.70 million in revenue each year. The medical research company earns $27.17 million in net income (profit) each year or $1.29 on an earnings per share basis. Abaxis employs 656 workers across the globe.
How can I contact Abaxis?
Abaxis' mailing address is 3240 WHIPPLE ROAD, UNION CITY CA, 94587. The medical research company can be reached via phone at 510-675-6500 or via email at [email protected]
MarketBeat Community Rating for Abaxis (NASDAQ ABAX)
MarketBeat's community ratings are surveys of what our community members think about Abaxis and other stocks. Vote "Outperform" if you believe ABAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
